NCT02588105
Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer Treatment NCT00037804
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction Treatment NCT02937116
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors Treatment NCT04731467
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors Treatment NCT04366648
Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor Treatment NCT04641871
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies Treatment NCT03454620
A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy Treatment NCT02884128
A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors Treatment NCT02250157
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Treatment NCT01463982
Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies Treatment NCT00786669
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors Treatment NCT00251407
Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies Treatment NCT00215501
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies Treatment NCT00079352
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors Treatment NCT00047242
UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors Treatment NCT00054288
Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors Treatment NCT00042874
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors Treatment NCT00003742
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors Treatment NCT00004051
Irinotecan in Treating Patients With Advanced Solid Tumors Treatment NCT00003970
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma Treatment NCT00003711
Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors Treatment NCT00003109
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors Treatment NCT00002759
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma Treatment NCT00006485
Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors Treatment NCT01282697
Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors Treatment NCT04256707
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment Treatment NCT03810742
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors Treatment NCT05086822
A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors Treatment NCT05086848
A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors Treatment NCT03245450
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors Treatment NCT02482441
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Treatment NCT02596503
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors Treatment NCT02392793
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies Treatment NCT01472016
Study of ABT-700 in Subjects With Advanced Solid Tumors Treatment NCT00993044
A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin Treatment NCT00990912
A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002) Treatment NCT02611024
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Treatment NCT02033551
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors Treatment NCT01770353
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment Other NCT00249977
Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan Treatment NCT01009073
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects Treatment NCT01528046
Metformin in Children With Relapsed or Refractory Solid Tumors Treatment NCT00186979
Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors Treatment NCT03318445
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair Treatment NCT02049593
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors Treatment NCT01141244
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors Treatment NCT00389584
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors Treatment NCT00138216
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Treatment NCT00101270
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Treatment NCT00110357
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors Diagnostic NCT00008424
Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants Treatment NCT00024284
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors Treatment NCT00016861
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors Treatment NCT00006095
Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy Treatment NCT00004919
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy Treatment NCT04238819
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma Treatment